Dr. Ian Smith Joins BioMark’s Board of Directors

Vancouver, British Columbia – (December 5th, 2017)–BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that Dr. Ian Smith has been elected to become a board director of the company.

Rashid Ahmed, President and CEO, says, “We are extremely excited to welcome Dr. Smith to our board. His achievements in medical research space will be a major asset to BioMark.  Dr. Smith’s diagnostic expertise, leadership and research experience brings depth and practicality as we begin to commercialize and position our technology for different oncology applications and potential linkages with strategic distribution partners.”

About Dr. Ian C.P. Smith, O.C., OFS, Ph.D., D.Sc., FRS(C)

Dr. Ian Smith is the Chair of CIMTEC’s Board of Directors. Dr. Smith began his National Research Council (NRC) career in Ottawa as a Research Officer specializing in magnetic resonance. In 1987, he became Director General of the NRC Institute for Biological Sciences, Ottawa.  In 1992, he founded the Institute for Biodiagnostics in Winnipeg as its first Director General.  The Institute focuses on the development and commercialization of medical devices for the non-invasive diagnosis of disease.

Dr. Smith is dedicated to early detection and treatment of disease and using this knowledge to advance the state of medicine and the economy. He is a passionate mover for the commercialization of the products of research, and has started nine companies with a present value of $300 million. In 2013, he retired from NRC to help build a spin-off company, Innovative Biodiagnostics, specializing in tests for colon cancer and breast cancer.

He was appointed Officer of the Order of Canada in 2008 for his leadership in the advancement, development and commercialization of Canada’s diagnostic technologies, notably magnetic resonance imaging, in the field of health care. In addition, Dr. Smith received the 2008 Outstanding Achievement Award of the Public Service of Canada, presented to individuals who have displayed long-term excellence throughout their careers in Canada’s public service. He was awarded the Queen’s Gold (2002) and Diamond (2012) Jubilee Medals for his contributions.

https://www.biomarkdiagnostics.com/Press Release – Dr. Ian Smith Joins BioMark’s Board of Directors

BIOMARK’s Clinical Trial & Research Update

Vancouver, British Columbia – (November 1, 2017) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX,
FSE: 20B, OTCMKTS: BMKDF) is pleased to provide the latest clinical trial update. The company
analyzed samples from the clinical trials samples at a Good Laboratory Practice (GLP) facility, which
utilized the Company’s internal standards (obtained under Health Canada’s Investigational Testing
Authorization application # 229838).
Listed below are the accomplishments thus far:

1. Clinical trial is still ongoing at Saint Boniface Research Centre (SBRC). Preliminary
analysis of data has been conducted for the 218 patient trial that was granted by Health
Canada under CTA# 156730. Majority of the diseased patients’ recruits for this study
were lung cancer patients.

2. The Canadian Principal Investigators (PIs) have reviewed the data with a biostatistician
and medical team from Bangladesh. The results are directionally very encouraging, and
both the groups have recommended further information/investigation on the control
population with specific inclusion / exclusion criteria due to a number of very high
outliers defined as subjects who were considered Healthy but exhibited high Acetyl
Amantadine concentrations. There is a need now for this control group cohort to be
followed to determine that they in fact could be cancer patients who have not
exhibited symptoms. Additional investigation on the control group has commenced
following a new ethics approval from health authorities in Bangladesh. We estimate that
it should last about 2 months for a first review of their condition. It is important to
demonstrate that there is a significant difference in assessment of persons who are
healthy versus cancer patients, and this cannot be done unless the outliers in the
control group are well characterized. A new control group consisting of 35 patients has
been recruited and samples collected from Bangladesh. This new group was selected
based on a modified inclusion/exclusion criteria and new data from this group will
further determine the impact of confounders that will be important when we introduce
the tests for clinical application.

3. Based on BioMark’s previous control studies in Canada, several subjects who were
considered Healthy exhibited high Acetyl Amantadine concentrations. The follow up of
these subjects required Ethics and Health Canada Approval i.e. for permission from
these participants to delve further into their conditions. The follow up studies have now
received St. Boniface research review committee approval. The necessary systematic
follow up on those persons with the principal investigator has now begun. This
information may be important for the development of the submission package to be
filed with Health Canada, and could demonstrate better accuracy and robustness in use
of our assay for predicting cancer prior to manifestation of symptoms of the disease
(again similar to point 2 above).

4. Clinical trial on measuring response to chemotherapeutic treatment will begin at
CancerCare Manitoba under the direction of Dr. Andrew Maksymiuk

Next Steps
As soon as all the data are received and tabulated, a comprehensive submission package
will commence. Our target date for submission is within 2-3 months after the
completion of the new incoming data analysis or earlier.

News_Release_-_BIOMARKs_Clinical_Trial_Update (PDF)

BIOMARK ANNOUNCES PATENT GRANTED IN CHINA

Vancouver, British Columbia – (October 25th, 2017) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX); (FSE: 20B); (OTCMKTS: BMKDF) is pleased to announce that its patent titled “A METHOD FOR ASSAYING THE ACTIVITY OF SPERMIDINE/SPERMINE N1-ACETYLTRASFERASE” has been prosecuted to allowance and issued in China.

Rashid Ahmed, President and CEO, says, “Granting of this patent expands and strengthens our portfolio beyond a single compound thus allowing the company additional freedom to select potentially better signaling candidates. Issuance of the patent in China is important as we accelerate our development in commercializing our technology platform for this prime diagnostic market. In addition, BioMark is now well positioned as far as expiration of its initial patent is concerned”.

About BioMark Diagnostics Inc.

BioMark is developing proprietary, non-invasive, and accurate cancer diagnostic solutions which can help detect, monitor and assess treatment for cancer early and cost effectively. The technology can also be used for measuring response to treatment and potentially for serial monitoring for cancer survivors.

Further information about BioMark is available under its profile on the SEDAR website www.sedar.com and on the CSE website www.thecse.ca.

For further information on BioMark, please Contact:
Rashid Ahmed Bux
President & CEO
BioMark Diagnostics Inc.
Tel. 604-282-6567
Email: info@biomarkdiagnostics.com

Forward-Looking Information:

This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of BioMark. Forward-looking information is based on certain key expectations and assumptions made by the management of BioMark. Although BioMark believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because BioMark can give no assurance that they will prove to be correct. Forward-looking statements contained in this press
release are made as of the date of this press release. BioMark disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

The CSE has not reviewed, approved or disapproved the content of this press release.

 

Press Release – BioMark Announces Patent Granted in China (PDF)

BIOMARK ANNOUNCES APPOINTMENT OF SCIENTIFIC AND MEDICAL ADVISORS

Vancouver, British Columbia – (October 2nd, 2017)– BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX)
(FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that it has appointed four distinguished experts
to its scientific and medical advisory team. Announcements related to each adviser will be made
through appropriate news release.

Over the past few months our new advisors have provided BioMark with excellent counsel on how to
fine tune our clinical trial protocol(s) and opened new opportunities for global collaboration. As
advisors, they will participate in scientific planning, research design, presenting to key medical opinion
leaders and evaluate our commercial strategy to successfully introduce our technology to the market.
An incentive plan was approved by Board of Directors that consisted of aggregated 420,000 shares
valued at 10 cents for services offered in 2017 fiscal year plus aggregated 350,000 options exercisable
at 15 cents under BioMark’s option plan and will vest over 3 years plus a negotiable travel allowance.

Rashid Ahmed, President and CEO, comments: “We are extremely excited to welcome our new
scientific and medical advisors to our company. Their demonstrated ability to lead, offer clinical design
wisdom and connect emerging technologies would be a tremendous boost to BioMark. This is what
BioMark needs as we transition into a successful commercial entity.”

About BioMark Diagnostics Inc.

BioMark is developing proprietary, non-invasive, and accurate cancer diagnostic solutions which can
help detect, monitor and assess treatment for cancer early and cost effectively. The technology can
also be used for measuring response to treatment and potentially for serial monitoring for cancer
survivors.

Further information about BioMark is available under its profile on the SEDAR website www.sedar.com
and on the CSE website www.thecse.ca.

For further information on BioMark, please Contact:
Rashid Ahmed Bux
President & CEO
BioMark Diagnostics Inc.
Tel. 604-282-6567
Email: info@biomarkdiagnostics.com

Forward-Looking Information:

This press release may include forward-looking information within the meaning of Canadian securities
legislation, concerning the business of BioMark. Forward-looking information is based on certain key
expectations and assumptions made by the management of BioMark. Although BioMark believes that
the expectations and assumptions on which such forward-looking information is based are reasonable,
undue reliance should not be placed on the forward-looking information because BioMark can give no
assurance that they will prove to be correct. Forward-looking statements contained in this press
release are made as of the date of this press release. BioMark disclaims any intent or obligation to
update publicly any forward-looking information, whether as a result of new information, future
events or results or otherwise, other than as required by applicable securities laws.

The CSE has not reviewed, approved or disapproved the content of this press release

 

Press_Release_BIOMARK_ANNOUNCES_APPOINTMENT_OF_SCIENTIFIC_AND_MEDICAL_ADVISORS (1) (PDF)